Biocompatibility and pathways of initial complement pathway activation with Phisio- and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery

Perfusion

Volumn 26, Issue 2, 2011, Pages 107-114

  Thiara, A S ^a   Mollnes, T E ^a,b,c   Videm, V ^d   Andersen, V Y ^a   Svennevig, K ^c   Kolset, S O ^c   Fiane, A E ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORDLAND HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

biocompatibility; complement pathways; CPB; inflammation; Phisio; PMEA

Indexed keywords

ACRYLIC ACID DERIVATIVE; COMPLEMENT; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3BBBP; COMPLEMENT COMPONENT C3BC; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4BC; HEMOGLOBIN; LACTATE DEHYDROGENASE; MYELOPEROXIDASE; NEUTROPHIL ACTIVATING PEPTIDE 2; PHISIO(PHOSPHORYLCHOLINE); PHOSPHORYLCHOLINE; POLY 2 METHOXYETHYL ACRYLATE; PROTEIN; SYNDECAN 1; TERMINAL COMPLEMENT COMPLEX; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; CARDIAC PATIENT; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT BLOOD LEVEL; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MALE; MATERIAL COATING; OPEN HEART SURGERY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT;

ACRYLATES; AGED; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; COMPLEMENT ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; POLYMERS;

EID: 79953089697     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/0267659110392438     Document Type: Article

References (26)

1. Zimmermann AK, Weber N., Aebert H., Ziemer G., Wendel HP Effect of biopassive and bioactive surface-coatings on the hemocompatibility of membrane oxygenators. J Biomed Mater Res B-Appl Biomater 2007 ; 80: 433-439.
2. Landis RC, Arrowsmith JE, Baker RA, et al. Consensus statement: defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass. Heart Surgery Forum 2008 ; 11: E316 - E322.
3. Feindt P., Litmathe J., Boeken U., Gams E. Anticoagulation during extracorporeal circulation under conditions of an ongoing systemic inflammatory response syndrome: effects of heparin. Perfusion 2005 ; 20: 11-15. (Pubitemid 40298230)
4. Videm V., Mollnes TE, Garred P., Svennevig JL Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1991 ; 101: 654-660.
5. Fosse E., Thelin S., Svennevig JL, et al. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: a European multicentre study. Eur J Cardiothorac Surg 1997 ; 11: 320-327. (Pubitemid 27096673)
6. Thiara AS, Andersen VY, Videm V., et al. Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response. Perfusion 2010 ; 25: 9-16.
7. Baykut D., Bernet F., Wehrle J., Weichett K., Schwartz P., Zerkowski HR New surface biopolymers for oxygenators: an in vitro hemocompatibility test of poly (2-methoxyethlacrylate). Eur J Med Res 2001 ; 6: 297-305.
8. De Somer F., van Belleghem Y., Caes F., et al. Phosphorycholine coating offers natural platelet preservation during cardiopulmonary bypass. Perfusion 2002 ; 17: 39-44. (Pubitemid 34071706)
9. Videm V., Nilsson L., Venge P., Svennevig JL Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass. Artif Organs 1991 ; 15: 90-95.
10. Fure H., Nielsen EW, Hack CE, Mollnes TE A neoepitope-based enzyme immunoassay for quantification of C1inhibitor in complex with C1r and C1s. Scand J Immunol 1997 ; 46: 553-557. (Pubitemid 28035415)
11. Wolbink GJ, Bollen J., Baars JW, et al. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993 ; 163: 67-76.
12. Garred P., Mollnes TE, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988 ; 27: 329-335. (Pubitemid 18076757)
13. Mollnes TE, Brekke OL, Fung M., et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002 ; 100: 1869-1877. (Pubitemid 34925168)
14. Mollnes TE, Lea T., Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985 ; 22: 197-202. (Pubitemid 15016794)
15. Mollnes TE, Redl H., Hogasen K., et al. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 1993 ; 91: 295-300. (Pubitemid 23045677)
16. Tevaearai HT, Mueller XM, Horisberger J., et al. In situ control of cardiotomy suction reduces blood trauma. ASAIO J 1998 ; 44: M380 - M383.
17. Gregoretti S. Suction-induced hemolysis at various vacuum pressures: implications for intraoperative blood salvage. Transfusion 1996 ; 36: 57-60. (Pubitemid 26057264)
18. Casati V., Gerli C., Franco A., et al. Activation of coagulation and fibrinolysis during coronary surgery - on-pump versus off-pump techniques. Anesthesiology 2001 ; 95: 1103-1109. (Pubitemid 33043224)
19. Sundaram S., Irvine L., Courtney JM, Taggart DP, Wheatley DJ, Lowe GDO. Patterns of blood response during cardiopulmonary bypass. Int J Artif Organs 1992 ; 15: 243-248
20. Pleym H., Wahba A., Videm V., et al. Increased fibrinolysis and platelet activation in elderly patients undergoing coronary bypass surgery. Anesth Analg 2006 ; 102: 660-667.
21. Mulivor AW, Lipowsky HH Inflammation- and ischemia-induced shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol 2004 ; 286: H1672 - H1680.
22. Harboe M., Mollnes TE The alternative complement pathway revisited. J Cell Mol Med 2008 ; 12: 1074-1084.
23. Bruins P., te Velthuis H., Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997 ; 96: 3542-3548. (Pubitemid 27513431)
24. Nilsson UR, Larm O., Nilsson B., Storm KE, Elwing H., Ekdahl KN Modification of the complement binding properties of polystyrene - effects of endpoint heparin attachment. Scand J Immunol 1993 ; 37: 349-354. (Pubitemid 23070511)
25. Harboe M., Ulvund G., Vien L., Fung M., Mollnes TE The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol 2004 ; 138: 439-446. (Pubitemid 39573623)
26. Videm V., Fosse E., Mollnes T.E., Garred P., Svennevig JL Time for new concepts about measurement of complement activation by cardiopulmonary bypass. Ann Thorac Surg 1992 ; 54: 725-731.